Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Time-restricted feeding (TRF) is a novel type of intermittent fasting that involves eating within a daily period of 10 hours or less, followed by fasting for at least 14 hours daily. Several studies in rodents report that TRF reduces body weight, improves blood sugar control, and reduces the risk of cardiovascular disease-even when food intake is matched to the control group or no weight loss occurs. Preliminary evidence suggests that TRF may also increase weight loss, fat loss, and reduce the risk of diabetes and cardiovascular disease in humans. This study will test whether TRF enhances fat loss and increases weight loss in adults with obesity, relative to conventional dieting alone. In addition, this study will determine whether TRF reduces risk factors for type 2 diabetes and cardiovascular disease and will measure the feasibility and acceptability of TRF.
In conjunction with the parent study described above, four ancillary studies will be conducted:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early Time-Restricted Feeding | Experimental |
| |
| Control Schedule | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Early Time-Restricted Feeding | Behavioral | Eat all meals between 7 am - 3 pm for an average of ≥6 days per week. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Fat loss and lean mass retention | Percent of weight lost as fat, as measured by dual-energy X-ray absorptiometry (DXA). Lean mass retention will be quantified as 100% minus percent of weight lost as fat (i.e., is measured in the same units). | 14 weeks |
| Weight loss | Change in body weight (kg), as measured by scale weight | 14 weeks |
| Absolute changes in body composition | Changes in total fat mass, lean mass, bone mass, and regional values (kg), as measured by DXA. (This will be secondary to the assessment of fat loss and lean mass retention as specified above.) | 14 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Fasting glucose | Fasting glucose (mg/dl) | 14 weeks |
| Fasting insulin | Fasting insulin (IU/L) | 14 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Appetite | Hunger and fullness as measured by Likert (1-5 scale) and visual analog scales (a 0-100 scale, with 0 meaning "Not at all" and 100 meaning "Extremely") | 14 weeks |
| Food intake | Energy intake and food intake in kcal/day, as measured using Remote Food Photography Method (RFPM) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Courtney M Peterson, Ph.D. | University of Alabama at Birmingham | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UAB Weight Loss Medicine Clinic | Birmingham | Alabama | 35205 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41941962 | Derived | Rehman Z, Altonji OM, Steger FL, Jamshed H, Richman JS, Warriner AH, Peterson CM. Do the Effects of Early Time-Restricted Eating Vary by Cardiometabolic Phenotype, Age, Sex, or Race? A Secondary Analysis of a Randomized Controlled Trial. J Nutr. 2026 Jun;156(6):101526. doi: 10.1016/j.tjnut.2026.101526. Epub 2026 Apr 5. | |
| 35939311 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Statistical analyses will be performed blinded.
Not provided
| Control Schedule | Behavioral | Eat all meals over a 12-hour or longer period for an average of ≥6 days per week. |
|
| Structured Weight Loss Program | Behavioral | A structured weight loss program with physical activity recommendations and dietary counseling. |
|
| HbA1c | HbA1c (%) | 14 weeks |
| Lipids | Total cholesterol (mg/dl), LDL cholesterol (mg/dl), HDL cholesterol (mg/dl), and triglycerides (mg/dl) | 14 weeks |
| Blood pressure | Systolic and diastolic blood pressure (mm Hg) | 14 weeks |
| Heart rate | Heart rate in beats per minute | 14 weeks |
| Waist circumference | Waist circumference (cm) | 14 weeks |
| 14 weeks |
| Macronutrient intake | % of calories as fat, carbohydrate, and protein, as measured using RFPM | 14 weeks |
| Meal frequency | Number of meals and snacks per day, as measured using RFPM | 14 weeks |
| Meal times | Clock times of meals and snacks, as measured using RFPM | 14 weeks |
| Times of eating | Start and stop times and mid-points of daily eating in clock time, as assessed by the daily adherence survey | 14 weeks |
| Duration of daily eating | Average duration of the daily eating period (hours), as measured by the daily adherence survey | 14 weeks |
| Distribution of food intake across the daytime | Distribution of calories eaten across the day in % per time period, as measured by a novel questionnaire that is being validated | 14 weeks |
| Breakfast and nighttime eating habits | Presence and degree of breakfast and nighttime eating, as measured by a novel questionnaire that is being validated | 14 weeks |
| Adherence | Self-reported adherence rate in days per week | 14 weeks |
| Reasons for non-adherence | Reasons for non-adherence, as measured by the daily adherence survey | 14 weeks |
| Retention | Attrition rate (%) | 14 weeks |
| Depression | Depression as measured by the Patient Health Questionnaire-9. (Each question is scored on a 0-3 scale, where 0 means "Not at all" and 3 means "Nearly every day." Answers to each question are tallied to create a single composite score of depression from 0-27, with higher values meaning more depressive symptoms.) | 14 weeks |
| Mood states | Mood states as measured by the Profile of Mood States (a 5-point scale with 1 meaning "Not at all" and 5 meaning "Extremely"). This study is particularly interested in the scores for anxiety and related moods. | 14 weeks |
| Chronotype | Chronotype/mid-point of sleep (in clock time), as measured by the Munich Chronotype Questionnaire | 14 weeks |
| Stimulant usage | Stimulant usage, as measured by the Munich Chronotype Questionnaire (in "servings" per time) | 14 weeks |
| Sleep duration | Sleep duration, as measured by the Pittsburgh Sleep Quality Index | 14 weeks |
| Sleep quality | Sleep quality, as assessed by the Pittsburgh Sleep Quality Index (PQSI) (This study will use the Global PQSI score, which ranges from 0-21, where higher values correspond to worse sleep quality.) | 14 weeks |
| Eating Behaviors | Restrained, emotional, and external eating, as measured by the Dutch Eating Behavior Questionnaire. (Individual questions are scored on a 5-point scale ranging from "Never" to "Very often," and composite scores for restrained, emotional, and external eating are tabulated, with higher numbers reflecting more of each trait.) | 14 weeks |
| Loneliness | Loneliness, as measured by the UCLA Loneliness Scale (a 3-point scale with 1 meaning "hardly ever" and 3 meaning "often") | 14 weeks |
| Intervention satisfaction | Intervention satisfaction and barriers and facilitators of adherence, as measured by qualitative exit interview | 14 weeks |
| Social life and daily habits | Social life and daily habits, as measured by the frequency of occurrence of social activities (5- and 8-point rating scales) | 14 weeks |
| Physical activity | Physical activity status, as measured by the Baecke Physical Activity questionnaire | 14 weeks |
| Plasma and salivary nitrate and nitrite | Plasma and salivary nitrate and nitrite (nM) | 14 weeks |
| Salivary nitrate reductase activity | Salivary nitrate reductase activity (nmol / min / colony forming unit) in tongue swab samples | 14 weeks |
| Salivary bacterial abundance | Salivary bacterial abundance (colony forming units) in tongue swab samples | 14 weeks |
| 24-hour urinary oxalate, citrate, sodium, calcium, chloride, potassium, and creatinine | 24-hour urinary oxalate, citrate, sodium, calcium, chloride, potassium, and creatinine, as measured in mg/day | 14 weeks |
| 24-hour urinary phosphorus and uric acid | 24-hour urinary phosphorus and uric acid, as measured in g/day | 14 weeks |
| 24-hour urinary aldosterone excretion | 24-hour urinary aldosterone excretion (µg/12 hr) | 14 weeks |
| 12-hour urinary sodium and potassium | 12-hour urinary sodium and potassium (mmol/12 hr) | 14 weeks |
| 12-hour urinary endothelin | 12-hour urinary endothelin (ng/12 hr) | 14 weeks |
| 12-hour urinary nitric oxide | 12-hour urinary nitric oxide (mmol/12 hr) | 14 weeks |
| 12-hour urinary albumin | 12-hour urinary albumin (mg/12 hr) | 14 weeks |
| 12-hour urinary KIM-1 | 12-hour urinary KIM-1 (pg/g creatinine or pg/12 hr) | 14 weeks |
| 12-hour urinary nephrin | 12-hour urinary nephrin (ng/g creatinine or ng/12 hr) | 14 weeks |
| 12-hour albumin-to-creatinine ratio | 12-hour albumin-to-creatinine ratio | 14 weeks |
| 12-hour urinary reactive oxidative stress | 12-hour urinary hydrogen peroxide and TBARs (µmol/g creatinine or µmol/12 hr) | 14 weeks |
| Urinary exosomes | Urinary exosomes (particles/ml) | 14 weeks |
| Jamshed H, Steger FL, Bryan DR, Richman JS, Warriner AH, Hanick CJ, Martin CK, Salvy SJ, Peterson CM. Effectiveness of Early Time-Restricted Eating for Weight Loss, Fat Loss, and Cardiometabolic Health in Adults With Obesity: A Randomized Clinical Trial. JAMA Intern Med. 2022 Sep 1;182(9):953-962. doi: 10.1001/jamainternmed.2022.3050. |
| 33512717 | Derived | Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, Zaman S, Salmasi AM, Tsilidis K, Dehghan A. Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2021 Jan 29;1(1):CD013496. doi: 10.1002/14651858.CD013496.pub2. |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |